Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-11 · 1881 (6) · 189709
DOI: 10.1016/j.bbcan.2026.189709 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-11. Verfasst von Xinran Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 168 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Shanghai Lingjun Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Epidermal growth factor receptor (EGFR) mutations represent a central oncogenic driver in non-small cell lung cancer (NSCLC). While EGFR tyrosine kinase inhibitors (TKIs) have revolutionized the management of NSCLC, acquired resistance remains a major hurdle. In response, antibody-based therapeutic strategies have gained increasing attention as a means to overcome TKI resistance and extend disease control. This review synthesizes the rapidly evolving landscape of antibody-based therapeutics for EGFR-mutant NSCLC. We first summarize the mechanisms of monoclonal antibodies directly targeting EGFR, including cetuximab and necitumumab, and discuss their therapeutic limitations. We then highlight the emergence of bispecific antibodies designed to simultaneously target EGFR and key resistance pathways, such as MET. In addition, we review combination strategies integrating EGFR inhibition with antibodies directed against alternative oncogenic pathways or the tumor microenvironment, including anti-angiogenic agents such as bevacizumab. A major focus of this review is antibody-drug conjugates (ADCs) targeting novel surface antigens, including HER2, HER3, and TROP2. By delivering highly potent cytotoxic payloads selectively to tumor cells, these ADCs have demonstrated remarkable clinical efficacy in EGFR TKI-resistant settings. Furthermore, we examine the complex and evolving role of immunotherapy in EGFR-mutant NSCLC. Beyond immune checkpoint blockade, we discuss emerging immunomodulatory strategies targeting the adenosine pathway (CD73), phagocytosis checkpoints (CD24), and complement regulatory proteins (CD55/CD59). Finally, we explore advanced antibody modalities, including immune-engaging bispecific antibodies and next-generation ADCs. Collectively, antibody-based therapies are reshaping the treatment landscape through diverse mechanisms, offering renewed promise for overcoming resistance and improving outcomes in EGFR-mutant NSCLC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China.
- Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China. Electronic address: lin.zongwu@zs-hospital.sh.cn.
- Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, PR China. Electronic address: czhan10@fudan.edu.cn.
Förderung
- China Postdoctoral Science Foundation
- Shanghai Lingjun Program
- National Natural Science Foundation of China
Zitieren
APA
Chen, X., Liang, J., Zhu, J., Huang, X., Hu, Y., Lin, Z., & Zhan, C. (2026). Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(6), 189709. https://doi.org/10.1016/j.bbcan.2026.189709
Vancouver
Chen X, Liang J, Zhu J, Huang X, Hu Y, Lin Z, et al. Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(6):189709. doi:10.1016/j.bbcan.2026.189709
BibTeX
@article{Chen2026,
author = {Chen, Xinran and Liang, Jiaqi and Zhu, Junkan and Huang, Xiaolong and Hu, Yidu and Lin, Zongwu and Zhan, Cheng},
title = {Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {6},
pages = {189709},
doi = {10.1016/j.bbcan.2026.189709}
}
EUVIMED